[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
复制标题
萘哌地尔对良性前列腺增生相关膀胱过度活动症患者的疗效：比较早晚用药疗效差异的前瞻性随机对照研究
DOI：
--
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
H. Kanetake
中科院分区：
文献类型：
--
作者：
H. Sakai;T. Igawa;T. Onita;M. Furukawa;T. Hakariya;M. Hayashi;F. Matsuya;Y. Shida;N. Nishimura;Y. Yogi;T. Tsurusaki;K. Takehara;Koichiro Nomata;Kazutaka Shiraishi;T. Shono;Daiyu Aoki;H. Kanetake
选取2006年6月~ 2008年3月间100例有良性前列腺增生（BPH）和膀胱过动症（BPH/OAB）症状的患者，随机分为早用药组(M)和晚用药组(E)，每天1次，早餐或晚餐后给予纳托地尔50 mg，连续8周。80例患者（M组43例，E组37例）进行疗效分析。纳哌地尔显著提高国际前列腺症状总分；M组从19.2±7.9降至11.7±5.8，E组从19.4±6.4降至12.3±6.8 (p<0.0001)， M组生活质量评分从4.9±0.8降至3.2±1.4，E组从5.0±0.8降至3.6±1.3 (p<0.0001)， M组OAB症状评分从7.8±2.6降至5.0±2.5 (p<0.0001)， E组从8.6±2.9降至5.8±3.3 （p<0.0001）。不良反应发生率M组（6.1%）与E组（2.2%）比较差异无统计学意义。这些结果表明，naftopidil改善储存症状和排尿症状，而与给药时间无关。
A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks. Data were available for efficacy analysis on 80 patients (M group ; 43, E group ; 37). Naftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group (p<0.0001), QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group (p<0.0001), and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group (p<0.0001) and from 8.6±2.9 to 5.8± 3.3 in the E group (p<0.0001). There was no significant difference in the incidence of adverse effects between the M group (6.1%) and E group (2.2%). These results suggest that naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration.
人脊髓中的α1-肾上腺素能受体：编码α1-肾上腺素能受体亚型的mRNA在四个不同水平上的特异性局部表达。
DOI：
10.1016/s0169-328x(98)00287-3
发表时间：
1999
期刊：
Brain research. Molecular brain research
影响因子：
--
作者：
Smith,MS;Schambra,UB;Wilson,KH;Page,SO;Schwinn,DA
通讯作者：
Schwinn,DA